SCLT1: A Protein Regulating Sodium Channels and Cell Signaling

Target Name: SCLT1

NCBI ID: G132320

SCLT1

SCLT1: A Protein Regulating Sodium Channels and Cell Signaling

SCLT1, or sodium channel and clathrin linker 1, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the sodium channels, which are responsible for transmitting electrical signals in and out of cells. SCLT1 has also been shown to play a role in the development and maintenance of various diseases, including heart disease, neurodegenerative diseases, and cancer. As a result, SCLT1 has become a focus of interest for researchers and pharmaceutical companies as a potential drug target or biomarker.

SCLT1 was first identified in the late 1990s as a gene that was expressed in a variety of tissues, including brain, heart, liver, and pancreas. It is a member of the superfamily of transmembrane protein (SMP) genes, which are responsible for the construction of the cell membrane. SCLT1 is characterized by its ability to form a complex with the protein clathrin, which is a key regulator of cell signaling. This interaction between SCLT1 and clathrin has important implications for the regulation of sodium channels, as SCLT1 is shown to play a role in the regulation of clathrin levels.

SCLT1 has been shown to be involved in a variety of physiological processes in the body, including the regulation of ion channels, neurotransmitter release, and cell signaling. One of the most well-studied functions of SCLT1 is its role in the regulation of sodium channels. SCLT1 is shown to play a negative role in the regulation of sodium channels, by inhibiting the activity of these channels. This means that when sodium channels are activated, SCLT1 is able to prevent them from opening, which can lead to a decrease in the amount of neurotransmitters that are released from the channels.

In addition to its role in the regulation of sodium channels, SCLT1 has also been shown to be involved in the regulation of other cellular processes. For example, SCLT1 has been shown to play a role in the regulation of cytoskeletal organization and cell migration. It is also involved in the regulation of cell adhesion, and has been shown to play a role in the development of cancer.

SCLT1 has also been shown to be a potential drug target, as it has been shown to interact with a variety of small molecules, including many that are used in drug development. For example, SCLT1 has been shown to interact with a variety of drugs that are used to treat a variety of conditions, including heart disease, neurodegenerative diseases, and cancer. This suggests that SCLT1 may be an attractive target for new drugs, and that its regulation by SCLT1 may be a useful diagnostic or therapeutic target in these diseases.

In conclusion, SCLT1 is a protein that is expressed in various tissues throughout the body and is involved in a variety of physiological processes, including the regulation of sodium channels and cell signaling. Its regulation of sodium channels has important implications for the regulation of ion flow and neurotransmitter release, and its involvement in a variety of cellular processes makes it a potential drug target or biomarker. Further research is needed to fully understand the role of SCLT1 in these processes and its potential as a drug target.

Protein Name: Sodium Channel And Clathrin Linker 1

Functions: Adapter protein that links SCN10A to clathrin. Regulates SCN10A channel activity, possibly by promoting channel internalization (By similarity)

The "SCLT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCLT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets